In conclusion, our findings identify not only disease severity but also initial treatment with piperacillin/tazobactam, predominantly used at standard doses, as independent negative predictors of early treatment response in patients with BSI caused by potential AmpC beta-lactamase producing Enterobacterales where pneumonia was the main focus of bacteremia. The gene discussed is LACTB; the disease is bacterial infectious disease with sepsis.